Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 26 ... please visit http://www.vaxinnate.com.Keywords: Health, Biotechnology, Pharmaceutical, Toxicology, Conservation, Ecology, Environment, Technology, 3M.This article ... its TLR agonists to VaxInnate for an undisclosed licensing fee, in addition to milestone and royalty payments."Pairing our TLR agonists with VaxInnate's innovative ... 3M Drug Delivery Systems has signed an agreement with VaxInnate Corporation under which ... increasing the effectiveness of vaccines," said Dr. Mark Tomai, PhD, Vaccine Business Development Director, 3M Drug Delivery Systems."The combination of VaxInnate's ...
2009 NOV 28 ... Health, Biotechnology, Clinical Trials, Infectious Diseases, Pharmaceutical, Research, Science, Electroni, Analogue, Common Stock, Finance, Financial, Investing, ... for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 ... of ongoing GLP studies, believe we are on track to file an investigational new drug application and initiate a Phase I clinical trial of INX-189 in the first half of ... make progress on all fronts, including the advancement of our differentiated antiviral development programs and most recently, the completion of a financing that we believe strategically ...
2009 NOV 26 ... technology. It has entered into several drug discovery collaboration projects with pharmaceutical partners, and built a pipeline of early drugdevelopment assets for cancer and ...
2009 NOV 24 ... Indian Company, engages in the manufacture, marketing, and distribution of pharmaceuticaland allied healthcare products in India and internationally.Natrol, Inc. has ... products are offered by U.S. health food, drug and grocery stores, mass-market retailers, Natrol.com, and other online retailers. More ... other members of our industry," says Dr. Michael T. Yatcilla, Natrol's Research and Development VP.† A natural product, Natrol® Carb Intercept®, used in conjunction with a ...
2009 NOV 25 ... its drugdevelopment independently and, when advantageous, collaborated with world-class pharmaceutical companies to access additional resources and expertise. Statement Regarding Adjusted ...
2009 NOV 24 ... into Singapore this year.Keywords: Health, Biotechnology, Clinical Trials, Pharmaceutical, Research, Other Science, Science, General Health, , Acquisitions, Asia, China, Data ... it has completed its acquisition of Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China. The acquisition strengthens ... research organizations in China. The acquisition strengthens PPD's full range of drugdevelopment services in the country and positions it to capitalize on the tremendous ...
2009 NOV 29 ... drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufacturers' operations. Using self-assembled monolayers, the team has been able to ... partners.Keywords: Chemicals, Chemistry, Engineering, Technology, Drug Development, Pharmaceuticals, Therapy, Treatment, University of Leeds.This article was ...
2009 NOV 24 ... researchers concluded: "Compatibility studies between NFX andpharmaceutical excipients, including three hydrophilic polymers were carried out in order to develop a ... of Thermal Analysis and Calorimetry, "Norfloxacin (NFX) is a synthetic antibacterial drug. The development of extended release tablets improves the patients' comfort and ...
2009 NOV 23 ... and its products, visit www.sucampo.com. Keywords: , Health, Biotechnology, Pharmaceutical, Research, Science, Asia, Japan, Software, Biopharmaceuticals, Drugs, Pharmaceutical ... bowel syndrome with constipation in adult women. Sucampo also is developing the drug for additional gastrointestinal disorders with large potential markets. In April 2009, ... an international biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of ...
2009 NOV 24 ... TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, ... of Julie Lekstrom Himes, M.D. to join TARIS in the position of Chief Medical Officer and Senior Vice President for Clinical Development. Dr. Himes has broad clinical research ...
2009 NOV 23 ... biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., ... needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration ...
2009 NOV 23 ... Keywords: , Health, Biotechnology, Clinical Trials, Oncology, Pharmaceutical, Consumer, Men, Biopharmaceuticals, Biotechnology, Chemotherapy, Clinical Research, ... eventually advance to CRPC. Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer related deaths among men in the U.S. ... antigen (PSA) levels. Notably, TOK-001 is the first investigational new drug that decreases androgen receptor levels in prostate cancer cells and the only prostate ... with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC. CRPC is an ...
2009 NOV 23 ... Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT), a specialty pharmaceutical company focused on the developmentand commercialization of proprietary products that ... that on October 28, 2009, the FDA issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo=AE (zolpidem tartrate sublingual tablet), the lead ...
2009 NOV 23 ... Commission on March 13, 2009. Keywords: HIV/AIDS, Health, Biotechnology, Pharmaceutical, Other Health, Mergers, Acquisitions, Advertising, Common Stock, Finance, Financial, ... Inc. (Nasdaq: TRMS) ("Trimeris") announced that in connection with the Agreement and Plan of Merger dated October 2, 2009, by and among Trimeris, Arigene Co., Ltd. and RTM ... dependent on third parties for the sale, marketing and distribution of the Company's drug candidates; the market for HIV therapeutics is very competitive with regular new product ... materially are the following: there is uncertainty regarding the success of research and development activities, regulatory authorizations and product commercializations; we are dependent ...
2009 NOV 23 ... For more information, contact B. Steffansen, University of Copenhagen, Faculty Pharmaceutical Science, Dept. of Pharmaceutical & Analyt Chemical, University of Pk 2, DK-2100 ... whether transporters were involved in the intestinal absorption of an organic anion A275 and to compare the impact of interactions related to transporters in the Caco-2 cell model ... to a study from Copenhagen, Denmark, "A key determinant for oral bioavailability of a drug candidate is the intestinal epithelial permeation of the drug candidate. This intestinal ... Washington, DC 20036, USA. Keywords: City:Copenhagen, Country:Denmark, Drug Development, Gastroenterology, Molecular Pharmacology, Molecular Therapies, Pharmaceuticals, ...
2009 NOV 23 ... rate from the stomach is mainly affected by the digestive state, the properties of the pharmaceutical formulation and the effect of drugs, posture and circadian rhythm." ... According to a study from Uppsala, Sweden, "Generally, gastric emptying of a drug to the small intestine is controlled by gastric motor activity and is the main factor ... City:Uppsala, Country:Sweden, Addiction Medicine, Alcoholism, Controlled Release, Drug Development, Drugs, Gastroenterology, Hydromorphone Hydrochloride, Mental Health, Molecular ...
2009 NOV 23 ... and has been a broadly pursued but extremely difficult target to drug within the pharmaceutical industry for many years. Within the bloodstream, renin initiates a series of reactions ... Vitae Pharmaceuticals, Inc., an integrated discovery and development company, announced the company's novel, clinical-stage renin inhibitor, VTP-27999, has ...
2009 NOV 23 ... Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both developmentand commercial capabilities focused on women's healthcare ... 250-member specialty sales force. In June 2009, Xanodyne received Food and Drug Administration (FDA) approval for Zipsor, a new treatment option for relief of mild to ...
2009 NOV 23 ... Keywords: , Health, Biotechnology, Clinical Trials, Oncology, Pharmaceutical, Food, Common Stock, Finance, Financial, Investing, Investment, Stock Market, ... Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing ... and to conclude enrollment. The company is in dialogue with the U.S. Food and Drug Administration (FDA) on the design and implementation of a registration trial, a study ... of operating expenses. For the third quarter of 2009, as compared to 2008, Research and Development expenses declined $2.6 million while General and Administrative expenses declined by ...
